DNA repair drugs are utilized in cancer treatment to interfere with DNA damage response and repair pathways in cancer cells. By blocking specific DNA repair mechanisms like homologous recombination, these drugs sensitize cancer cells and enhance the effectiveness of chemotherapy and radiation. They help overcome chemotherapy resistance and restore chemotherapy sensitivity. DNA repair inhibitors are developed to target key proteins involved in mismatch repair, base excision repair, nucleotide excision repair and non-homologous end joining pathways.

The DNA Repair Drugs Market is estimated to be valued at US$ 6.28 Bn in 2023 and is expected to exhibit a CAGR of 6.5% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:
One of the major trends in the DNA repair drugs market is the rise in development of PARP inhibitors. PARP inhibitors work by blocking the activity of PARP enzymes that help cancer cells repair DNA damage caused by chemotherapy or radiation therapy. They are being extensively researched and developed for several cancer types like breast, ovarian and prostate cancer with defective BRCA genes. Olaparib became the first FDA approved PARP inhibitor in 2014 and many other PARP inhibitors are in clinical trials. Besides PARP inhibitors, DNA damage response inhibitors targeting ATM, ATR, DNA-PK and Chk1/Chk2 proteins are also gaining significant attention in precision oncology.

Porter's Analysis
Threat of new entrants: The threat of new entrants is low as DNA repair drugs market requires huge R&D investments and regulatory approvals.

Bargaining power of buyers: The bargaining power of buyers is moderate as the drugs have limited substitution and there are few established players in the market.

Bargaining power of suppliers: The bargaining power of suppliers is moderate as raw material suppliers have availability of alternative buyers in pharmaceutical industry.

Threat of new substitutes: The threat of new substitutes is low as DNA repair drugs provide targeted treatment with limited side effects.

Competitive rivalry: The competitive rivalry is high as the market is dominated by few major players.

SWOT Analysis
Strength: DNA repair drugs provide precision medicine approach with targeted action and limited side effects.

Weakness: High R&D costs and lengthy development and approval timelines of new drugs.

Opportunity: Rising cancer incidence worldwide and growing genomic research into DNA repair mechanisms.

Threats: Patent cliff of major drugs and introduction of generics eroding market share of innovators.

Key Takeaways
The global DNA repair drugs market size is expected to witness high growth, exhibiting CAGR of 6.5% over the forecast period, due to increasing cancer prevalence worldwide.

Regionally, North America dominates the global market currently owing to growing awareness and availability of advanced treatment options. Asia Pacific is expected to be the fastest growing market due to rising healthcare expenditure and increasing incidence of cancer.

Key players operating in the DNA repair drugs market are AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Co., Eli Lilly and Co., F. Hoffmann-La Roche AG, Gilead Sciences, Inc., GlaxoSmithKline PLC, Johnson & Johnson, Merck & Co., Inc., Merck KGAA, Novartis AG, Pfizer Inc., and Sanofi S.A. Major players are focusing on developing targeted therapies through ongoing clinical trials and acquisitions.

Get more insights on this topic: https://www.feedsfloor.com/other/dna-repair-drugs-market-complex-area-involving-several-biological-pathways-and-molecular